$11.428
-0.247 (-2.16%)At close
INKT Comparative Benchmarking
In the context of the broader market, INKT competes directly with industry leaders such as IMA and ELOX. With a market capitalization of $57.51M, it holds a significant position in the sector. When comparing efficiency, INKT's gross margin of N/A stands against IMA's N/A and ELOX's N/A. Such benchmarking helps identify whether Mink Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Mink Therapeutics Inc Financial Performance
The company has been experiencing significant net losses, with Q2 2026 net loss at $3.1 million and a consistent negative EPS trend, with the latest at -0.62. The current ratio is 1.23, indicating some liquidity, but overall financial health appears weak.
Financials
FY2026Q2
YoY:
-12.78%
-3.22M
Operating Profit
FY2026Q2
YoY:
-26.18%
-3.13M
Net Income after Tax
FY2026Q2
YoY:
-41.51%
-0.62
EPS - Diluted
FY2024Q3
YoY:
-29.23%
-3.00M
Free Cash Flow
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。